Research programme: tubulin polymerisation inhibitors - Myrexis

Drug Profile

Research programme: tubulin polymerisation inhibitors - Myrexis

Alternative Names: MPI-0443803; MPI-443803

Latest Information Update: 26 Nov 2012

Price : $50

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 30 Jun 2010 Myriad Pharmaceuticals is now called Myrexis
  • 22 Apr 2009 Preclinical trials in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top